Adverse effects of biologics: a network meta-analysis and Cochrane overview. 103.26.45.21 Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Aiming to explore the log Hazard Ratio(logHR) association to achieve an ACR70 response, a meta-regression analysis was performed, wherein the ABA treatment effects depended on the study follow-up, on the presence of TNFi therapies in the control arm, and on the mean baseline HAQ score [16]. Research Highlight 22 May 2023 Failure of cartilage regeneration: emerging hypotheses and related therapeutic strategies Sathish Muthu Jasmijn V. Korpershoek Ivan Martin Review Article 09 Jun. This study followed PRISMA statement [11]. Some important limitations must be emphasized. The Arthritis and Rheumatology Impact-Faktor IF 2022-2023 is 15.483. Cochrane handbook for systematic reviews of interventions. Diretrizes Metodolgicas. Arthritis and Rheumatology Impact-Faktor IF 2022-2023 | Analyse, Trend In the case of TNFi users, it is more obvious to think that marginal gain with a second bDMARDs will be smaller than individuals not taking TNFi. Health Econ. You can email the site owner to let them know you were blocked. 2015;350:aaa6516. PubMed As shown in Table 1, the exclusion of such studies did not modify the results. A longitudinal cohort study, by Witkam et al. Research Ranking (Medicine) 339. Ann Rheum Dis. With the present results, it is advisable to evaluate the introduction ABA or RTX before TCZ in refractory RA. Preventing rheumatoid arthritis: Lessons from that of type 1 diabetes Article This systematic review used a NMA to investigate efficacy of RTX, TCZ or ABA in patients with RA in RCTs. Arthritis & rheumatology (Hoboken, N.J.) - Cornell University Arthritis Rheum. 2011;70:26671. Traditionally used as a first-line treatment after methotrexate (MTX) failure, therapy with tumor necrosis factor inhibitors (TNFi) improves the quality of life of most individuals with RA. Citescore: 7.6. N Engl J Med. Seminars in Arthritis and Rheumatism. The impact score (IS) 2022 of Arthritis Care and Research is 3.78, which is computed in 2023 as per its definition. Your privacy choices/Manage cookies we use in the preference centre. Cloudflare Ray ID: 7e3f69fb1e679972 Both these characteristics reduce the propensity of trials with ABA to drive an ACR70 response. GC: received speaker fees from AbbVie, Pfizer, BMS, Roche, Lilly, and Novartis; LSFC: Speaker/Consultant fees from Abbott, American Heart Association, Roche, Amgen, NovoNordisk, Libbs. Updated impact factors on W eb of Science Journal Citation Reports (Ranking 2021) 1. This website is using a security service to protect itself from online attacks. Gwinnutt JM, Wieczorek M, Balanescu A et al. As shown in Table 2, each 0.1 point over the mean baseline HAQ in each study was associated with a RR of 2.043 (95%CI 1.03214.44, p for difference=0.028, R2=13%, I2=89%, p for heterogeneity0.001) for achieving an ACR70 response (Additional file 1: Fig. Impact Factor (IF) Total Articles: Total Cites: 2022 (2023 update)--2021--2020--2019--2018--2017--2016--2015: 8.955: 0: 45624: 2014: 7.764: 0: 46886: 2013: 7.871: 331: 46884: 2012: 7.477: 411: 45200: 2011: 7.866: 406: 43887: 2010: 8.435: 382: 44602 Primary and secondary outcomes were assessed. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Arthritis Rheumatol. 1 presents an important imbalance among studies in the frequency of TNFi treatment in the control arm. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Arthritis and Rheumatology 2022-2023 Journal's Impact IF is 15.483. The present NMA showed no significant differences between tocilizumab, abatacept and rituximab to achieve ACR70 response in six months in patients with RA refractory to methotrexate or TNFi agents, but these findings yielded high heterogeneity. The primary outcome was considered as achieving ACR70 response. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Cancer Drug Development Forum (CDDF) multi-Stakeholder workshop on Impact of the Microbiome on Cancer Growth and Therapy is organized by Cancer Drug Development Forum (CDDF) and will be held from Feb 15 - 16, 2019 at Right of the Isar Hospital, Munich, Bavaria, Germany. In contrast, there are two important issues to be considered as limitations to the interpretation of these results. The findings of our NMA comply with that of three previous meta-analyses[7,8,9]. Additionally, it contributes to cost-effectiveness analyses establishing which drug could bring the best balance between gains in quality of life and morbidity reduction in relation to the costs of therapies [40]. Therefore, the association between obesity and CRP levels observed by Witkam et al. Social factors play a crucial role as shown increasingly by a large body of evidence . Please include what you were doing when this page came up and the Cloudflare Ray ID found at the bottom of this page. For RTX, six studies were selected [26,27,28,29,30,31], where 350 (23.5%) patients in the intervention arm and 107 (12%) patients in the control arm achieved an ACR70 response at six months, indicating a HR of 2.43 (95% CI 1.992.96 p<0.001, I2=64% p for heterogeneity<0.001). Taking the wider perspective, according to the WHO obesity represents a global epidemic, and there is an ongoing and unmet need to tackle this epidemic. CDDF multi-Stakeholder workshop on Impact of the Microbiome on Cancer The primary outcome of such study consisted of drug retention without the occurrence of death from any cause, discontinuation of the drug studied, initiation of a new biologic or a combination of conventional disease-modifying antirheumatic drugs or increase in the dose of oral corticosteroids at more than 10mg a day at two consecutive visits. Rheumatology International | Home - Springer 2005;353:111423. The Rayyan QCRI application (RayyanSystems Inc., MA,EUA) was used to manage duplicate files. Background TNFi: percentage of individuals on tumor necrosis factor (TNF) inhibitors; HAQ: Health Assessment Questionnaire score; ABA: abatacept; RTX: rituximab; TCZ: tocilizumab; ACR: American College of Rheumatologists. Secondly, the NMA does not compensate for other factors unrelated to the drugs that make up the treatment arms [43]. Statistical analyses were performed using the R Studio software, version 1.1.4 (R v.4.0.1 and R_Studio v.1.1.463, Auckland, NZ) [19]. You can email the site owner to let them know you were blocked. Stat Med. Finally, the longer the exposure time to bDMARDs after 6months may increase the chance to identify new individuals with disease flares or therapy failures. These 3 explanatory variables were found after exploring all potential predictors of ACR70 response such as percentage of women, glucocorticoid use, patients' age, MTX dose, duration of RA, baseline HAQ, baseline DAS28, study follow-up time and frequency of TNFi treatment in the control arm. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data. Click to reveal Another potential limitation is the number of comparisons made for this analysis, which may favor spurious associations. Meta-regressions were conducted to assess the impact of treatments on the ACR70 response in a manner adjusted to the baseline HAQ score, study follow-up time (total study duration), and frequency of TNFi treatment in the control arm (Additional file 1: Fig. Example: the higher the follow-up time (suffix "_neg.vs. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, et al. A good EULAR response was defined as a decrease in disease activity score in 28 joints erythrocyte sedimentation rate (DAS28-ESR) more than 1.2 points and resulting score 3.2 or less. Patients may have been treated with different doses or for different TNFi treatment durations before considering an IR. Gaultney J, Benucci M, Iannazzo S, Nappi C, Sion K, Sabater FJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. This website is using a security service to protect itself from online attacks. Impact Factor. Check Out IF Ranking, Prediction, Trend & Key Factor Analysis. Arthritis Care and Research IS is decreased by a factor of 0.08 and approximate percentage change is -2.07% when compared to preceding year 2021, which shows a falling trend. In health and disease, both biological and non-biological factors play an important role. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Arthritis Care & Research - Wiley Online Library In other words, it is not solely the biological and genetic make-up that define health status. The Lancet Rheumatology. Successive paradigm shifts have marked the treatment of rheumatoid arthritis (RA) in the past two decades. . Trial-based cost-effectiveness of abatacept for rheumatoid arthritis patients in Italy. Study data were independently assessed by two investigators. S4A) and each additional month of follow-up was associated with a RR of 0.980 (95% CI 0.9610.996, p for difference=0.048, R2=9%, I2=71%, p for heterogeneity0.001) for achieving an ACR70 response. Aims and scope. Parenting is one of the most complex and challenging jobs you'll face in your lifetime -- but also the most rewarding. J Rheumatol. The action you just performed triggered the security solution. Ann Rheum Dis. In the second stage, the investigators independently evaluated the full text of the articles and made their selections according to the pre-specified eligibility criteria. 2008;59:78593. Your IP: Correspondence to This journal is published monthly by The Journal of Rheumatology Publishing Co. Ltd. 2014;41:21626. It is widely recognized that treatment intervention in patients with rheumatoid arthritis (RA) at early stages is associated with improved outcomes. Our aim was to compare the efficacy of rituximab, tocilizumab, and abatacept in individuals with rheumatoid arthritis (RA) refractory to treatments with MTX or TNFi agents. Immediate Open Access: The Good, the Bad, and the Impact on Academic Society Publishing. The impact factor (IF) is calculated by counting citations from peer-reviewed journals only. De Impactfactor voor 2022-2023 van Arthritis and Rheumatology is 15.483 More Impactfactor Analyse, Trend, Ranglijst & Voorspelling. A moderate EULAR response was defined as a decrease in DAS28-ESR more than 0.6 points and resulting score 5.1 or less [38]. Thank you for submitting a comment on this article. useof impact factors of science journals easier. Treatments with rituximab (RTX), abatacept (ABA), and tocilizumab (TCZ) are available options [3,4,5]. The authors speculate that this observation may be in part explained by a stronger relationship between lower socioeconomic position and obesity in women. However, adiposity (fatness) is not necessarily truly reflected in level of BMI. These three drugs have demonstrated good efficacy compared to placebo, and similar or greater efficacy vs adalimumab in head-to-head clinical trials, however, there are no head-to-head studies comparing efficacy between them [19, 31]. 2008;67:4028. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Briggs AH, OBrien BJ. For the chances of achieving an ACR50 response, we selected the same studies as selected for the ACR70 response in six months. Performance & security by Cloudflare. Supervision: LSFC, MAGG. Additionally, the presence of an TNFi therapy in the control arm of any RCT was associated with a RR of 0.316 (95% CI 0.1340.746, p for difference=0.009, R2=27%, I2=85%, p for heterogeneity0.001) (Additional file 1: Fig. Recent Articles - The Lancet Rheumatology - Journal - Elsevier Advances in Rheumatology | Home The action you just performed triggered the security solution. 2014;66:165361. Sensitivity analyses were performed by excluding the trials with the longest exposure duration (in patient-years) by drug class. Multiple components of deprivation (e.g. There are three network meta-analyses [6,7,8] available comparing drugs used in the treatment of patients with RA refractory to TNFi or MTX therapies. Thank you to all our authors, reviewers and Editors who have made such valuable contributions to the journal! 2016;20:1610. However, the statistical power achieved in this study suggests that chances of false negative results are extremely low. For TCZ, six studies were selected [32,33,34,35,36,37], with 294 (18.5%) patients in the intervention arm and 97 (11%) patients in the control arm achieving an ACR70 response at six months, with a HR of 1.53 (95% CI 1.241.89 p=0.002, I2=76% p for heterogeneity<0.001) (Additional file 1: Fig. Cloudflare Ray ID: 7e3f6a2e2a9fef8c Google Scholar. Cochrane Database Syst Rev. 2011;70:20037. BMC Rheumatology | Home - BioMed Central MBB: Has participated in clinical and/or experimental studies related this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Cite this article. The primary outcome was an ACR70 response according to the American College of Rheumatology (ACR) criteria, i.e., at least 70% improvement in the number of swollen and painful joints and improvement in three of these five parameters: physician's global assessment of the disease, patient's global assessment of the disease, patient's assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and Health Assessment Questionnaire (HAQ) score. S4B). Impact factor: 5.431. Arthritis and Rheumatism Impact Factor IF 2023|2022|2021 - BioxBio Rheumatology | JAMA Network R Foundation for Statistical Computing, Vienna, Austria. Just articles in English and that were published in full were selected. RCTs with TCZ less often included TNFi agents in the control arm: ABA, 50%; RTX, 43%; and TCZ, 17% (p=0.048). The death of cost-minimization analysis? Makowski AC, Kim TJ, Luck-Sikorski C, Von Dem Knesebeck O. Nikiphorou E, Norton S, Carpenter L et al. Hazard ratios for achieving an ACR70 response at six months were not different among the bDMARDs, however, we found high heterogeneity. In contrast, abatacept was associated with RR=2.217 (95%CI 1.5543.161, p<0.001) for ACR70 compared to tocilizumab. A longitudinal cohort study', by Witkam et al. Impact-Faktor IF Analyse, Trend, Ranking & Vorhersage. Only RCTs that used the ACR response criterion (20, 50 and/or 70) and whose exposure to therapy (either intervention or control) was at least 24weeks were considered eligible. 2012;71:13038. In the second stage, the investigators independently evaluated the full text of the articles and made their selections according to the pre-specified eligibility criteria. The action you just performed triggered the security solution. Braslia: Ministrio da Sade; 2014. http://bvsms.saude.gov.br/bvs/publicacoes/diretrizes_metodologicas_sistema_grade.pdf. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Read the full text. 2001;10:17984. About The Journal of Rheumatology. The scope of Rheumatology includes a range of rheumatological conditions, musculoskeletal medicine, surgery and translational research. The journal publishes high-quality articles reporting on original investigations in all aspects of rheumatology-related research (basic science, clinical science, epidemiology, health outcomes, health policy, and education) as well as reviews and commentaries. Click to reveal Research Impact Score*: 6.2. Full systematic review data and codes in R for data processing and meta-analysis are available under request. Thus, in multivariate meta-regressions compensating for the effect of unbalanced characteristics, it is suggested that the use of ABA increases the chance of achieving an ACR70 response compared to the use of TCZ. Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment. BMC Med Res Methodol. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging.. 74. Rheumatology & Autoimmunity - Wiley Online Library 6.2. The term search was focused on titles, keywords, and abstracts. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. For all analyses, there was a slight inconsistency between direct and indirect measures (Table 1, Indirect comparisons among bDMARDs), but they showed a substantial heterogeneity among RCTs (>40%) (Additional file 1: Fig. Compared efficacy of rituximab, abatacept, and tocilizumab in patients CAS Dias S, Sutton AJ, Welton NJ, Ades AE. A suggested explanation centres on links between adiposity and inflammation and immunological changes that may drive active disease [6]. Your US state privacy rights, Click to reveal In: Higgins JPT, Green S, editors. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. 2013;33:61840. You can email the site owner to let them know you were blocked. Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, et al. Using the afore mentioned search terms and platforms, we identified 600 citations (details in Additional file 1 section). The action you just performed triggered the security solution. You can email the site owner to let them know you were blocked. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximabs Efficacy in MTX iNadequate rEsponders (SERENE)). Best Practice & Research Clinical Rheumatology | Journal Your IP: Additionally, the higher disease activity scores in obese patients have been shown by Witkam et al. Rheumatology maintains a focus on high societal impact in the form of contextual podcasts, videos and extended social media presence, and utilizing alternative metrics to support dissemination from Day 1 of publication. Fischhoff B. Such comparisons, unfortunately, will probably never be carried out. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. those patients with high pain, fatigue and sleep disturbance scores as assessed by the Rheumatoid Arthritis Impact of Disease (RAID . Five-year impact factor n/a. Based on the result of multivariate meta-regressions, by mathematically equalizing the conditions of the RCTs, we estimate that ABA could increase the chance of reaching an ACR70 response by 2.2-fold compared to TCZ. Through this web page, researchers can check the impact factor, total citation, journal quartile, and journal aim & scope. A journal impact factor is frequently used as a proxy for the relative importance of a journal within its field. This website is using a security service to protect itself from online attacks. In . Through the present study, it is possible to conclude that ABA, TCZ, and RTX have a similar efficacy when accounting solely the effects of co-treatments, but when accounting the full spectrum of unbalanced factors across RCT arms, our findings suggest that ABA increases the chance of achieving an ACR70 response in comparison to TCZ. Visit the ACR Abstracts website. Using data from the multicentre, prospective observational cohort Rheumatoid Arthritis Medication Study (RAMS) over 12months, Witkam et al. Arthritis and Rheumatology 2022-2023 | | | Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. The meta-analysis included 19 RCTs, with 7,835 patients and a mean study duration of 1.2years. BMC Rheumatology is an open access, peer-reviewed journal that considers pre-clinical, translational and clinical articles on all aspects of the prevention, treatment and management of rheumatological diseases, related systemic and inflammatory conditions and associated comorbidities, as well as epidemiology, education, pathophysiology, genetics. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. These dates may be modified as official changes are announced, so please check back regularly for updates. Chronic pain: definitions and diagnosis | The BMJ A narrative review, Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients, 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis, 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases, Social deprivation, gender and obesity: multiple stigma? In general, unpublished studies and observational studies could have a different impact on the results; however, there is great heterogeneity in terms of selection and statistical treatment in observational studies, which could hinder the data analysis. Nevertheless, the study makes the important point that both deprivation and obesity are associated with worse disease outcomes. of scholarly journals that accounts for both the number of citations Drafting of the manuscript: LSFC, ABO, AP. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. Explore the latest in rheumatology, including advances in therapy for rheumatoid and psoriatic arthritis and other connective tissue diseases. 2016;45:2626. Additional file 1: Fig. 5.5. Top Journals in Rheumatology. The ACR20, ACR50, and ACR70 responses refer to an improvement of 20%, 50%, and 70% in the ACR score, respectively. Research Ranking (Immunology) 40. Impact factor (IF) is a scientometric factor based on the yearly average number of citations on articles published by a particular journal in the last two years. Actigraphy-derived physical activity levels and circadian rhythm Statistical analysis: LSFC, ABO. Correspondence to: Elena Nikiphorou, Centre for Rheumatic Diseases, Kings College London, Weston Education Centre, 10 Cutcombe Rd, Brixton, London SE5 9RJ, UK. However, we believe that RCTs that select individuals with better quality of life at baseline (despite uncontrolled RA) may have unmeasured factors (biological, psychological, social) that may increase their response of TCZ, ABA or RTX.